Residential Rehab

There are currently no FDA-approved medications specifically for methamphetamine use disorder. Behavioral treatments such as contingency management have the strongest established evidence.

Stimulant use disorder is a diagnosable pattern of cocaine, methamphetamine, prescription stimulant, or other stimulant use that causes significant impairment or distress.

Phenobarbital is a long-acting barbiturate that can be used by experienced clinicians to manage alcohol withdrawal in selected patients, especially when benzodiazepines are unsuitable or withdrawal is difficult to control.

Benzodiazepine withdrawal can occur after physical dependence develops. Abrupt discontinuation can cause severe symptoms, including seizures and delirium, so gradual medically supervised tapering may be necessary.

Disulfiram is an FDA-approved medication for alcohol use disorder that causes an unpleasant reaction if alcohol is consumed, helping support abstinence in appropriately selected patients.

Naltrexone is an FDA-approved medication for alcohol use disorder that can reduce alcohol’s rewarding effects and help some people reduce heavy drinking or maintain recovery goals.

Acamprosate is an FDA-approved medication for alcohol use disorder that helps support continued abstinence after someone has stopped drinking.

Three FDA-approved medications are commonly used for alcohol use disorder: naltrexone, acamprosate, and disulfiram. They work differently and are selected based on the person’s goals, health, and treatment plan.

Wernicke encephalopathy is an acute neurologic emergency caused by severe thiamine deficiency. Heavy alcohol use raises risk by contributing to poor nutrition and impaired thiamine absorption and use.

Thiamine, or vitamin B1, is commonly given during alcohol withdrawal treatment because heavy alcohol use can cause thiamine deficiency and increase the risk of Wernicke encephalopathy.